Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
REALiTEC: a multi-country observational study of teclistamab in relapsed/refractory myeloma outside trials finds ORR 60.2%, ≥VGPR 52.2%; DoR 20.3 mos, PFS 9.7, OS 26.3; infections in 70.8% and CRS 55.8%; IgG given in 60%.”
Title: REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
Authors: Katarina Uttervall, Martin Kortum, Aurore Perrot, Sarah Farmer, Michele Cavo, Bhuvan Kishore, Caroline Jacquet, Maria Casanova, Markus Hansson, Katja Weisel, Hila Magen, Carmine Liberatore, Charlotte Hansen, Moshe Gatt, Tamir Shragai, Matteo Da Via, Teresa Alvarez, Mathew Streetly, Marc Raab, Salomon Manier, Jesper Aegesen, Claire Albrecht, Peter Hu, Pavel Smirnov, Diptendu Santra, Eva Rubio-Azpeitia, Rakesh Popat
You can read the Full Article in Haematologica.
You can find other articles featuring Robert Z. Orlowski on OncoDaily.
